

Supplementary Information




Fig. S1 3D network structure of the polymer **1** with channels along crystallographic *c* direction

Table S1 Selected parameters for weak hydrogen bonding interactions in complex **1**

D–H···A	H···A	D···A	D–H···A	Symmetry Code
O3–H3A···Cl2	2.27	3.162(7)	172	-x, -y, 2-z
C4–H4···N2	2.70	3.584(1)	154	2-x,-y,2-z
C7–H7A···Cl2	2.68	3.590(1)	159	x+1,+y,+z
C6–H6···Cl1	2.75	3.487(2)	133	-x+1,-y+1,-z+1




Fig. S2 IC₅₀ values of compound **1** in cancer (DL cells) and normal (PBMC) cells.

Table S2 Cell cytotoxicity of compound **1**, metal salt and 4-CNpy in DL cells. Data represents % cell death as compared to respective untreated control. ND: Not determined.




Dose (μM)	% Cytotoxicity		
	Compound 1	Metal salt	4-CNpy
1	38	0	0
5	28	0	0
10	25	0	0
20	37	0	0
40	55	2	3
60	66	4	4
80	72	5	5
100	83	5	7
IC ₅₀	37.03±3.12	ND	ND

Table S3 Cell cytotoxicity of compound **1**, metal salt and 4-CNpy in normal (PBMC) cells. Data represents % cell death as compared to respective untreated control. ND: Not determined.

Dose (μM)	% Cytotoxicity		
	Compound 1	Metal salt	4-CNpy
1	13	0	0
5	17	0	0

10	14	0	0
20	18	0	0
40	22	2	3
60	28	2	4
80	35	4	4
100	40	5	5
120	48	5	5
140	55	5	4
160	62	6	6
180	70	6	6
200	78	6	7
IC ₅₀	135.34±5.11	ND	ND

Table S4 The binding affinity demonstrated that compound **1** interacted with anti-apoptotic proteins with strong binding energy and the results were comparable with reference inhibitors.

Receptors	Reference ligands	Structures of the reference ligands	Docking score of the reference ligands	Docking scores of compound 1
BCL-2 (PDB ID: 2O22)	N-[(4-{[1,1-dimethyl-2-(phenylthio)ethyl]amino}-3-nitrophenyl)sulfonyl]-4-(4,4-dimethylpiperidin-1-yl)benzamide		-172	-148
BCL-XL (PDB ID: 4QVX)	2-[8-(1,3-benzothiazol-2-ylcarbonyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid		-145	-120
MCL-1 (PDB ID: 5KU9)	(3-{S})-3-azanyl-4-(4-bromophenyl)-~{N}-[(3~{S})-1-[2-[[{(2~{R})-1-(3,4-dichlorophenyl)-4-(methylamino)-4-oxidanylidene-butan-2-yl]amino]-2-oxidanylidene-ethyl]-2-oxidanylidene-4,5-dihydro-3~{H}-1-		-132	-98

	benzazepin-3-yl butanamide			
--	-----------------------------------	--	--	--